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Abstract
Background: Data from a feasibility study suggest that the use of an inelastic, short-stretch compression bandage
following total knee arthroplasty is a safe technique that may improve patient-reported health outcomes, and that
it is feasible to recruit to a full-scale study.
Methods: We will conduct a randomised controlled trial (RCT) of 2600 adult patients, which has 80% power to
detect a 1 point difference in the Oxford Knee Score (a patient self-reported assessment of knee pain and function)
at 52 weeks. Short stretch compression bandaging will be compared with standard wool and crepe bandaging
following total knee arthroplasty. Recruitment will take place in orthopaedic units across the United Kingdom.
Secondary outcomes include the EuroQol 5 Dimensions (EQ-5D)-5 L and EQ-5D-3 L scores, pain, length of hospital
stay, and complications.
Discussion: The Knee Replacement Bandaging Study (KReBS) is a large study which aims to contribute to the
evidence base for informing clinical decisions for the use of compression bandaging following knee arthroplasty.
Trial registration: International Standard Randomised Controlled Trial Register, ISRCTN 87127065. Registered on 20
February 2017.
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Background
Total knee arthroplasty (TKA) is a common and highly
successful operation in the management of osteoarthritis
[1]. Between 2003 and 2016 more than 870,000 entries
for primary TKA were submitted to the 14th National
Joint Registry report for England, Wales, Northern
Ireland, and the Isle of Man [2]. Post-operative knee
swelling is common and results in decreased functional
performance which in turn can lead to delayed rehabili-
tation, an increase in length of hospital stay, and a de-
crease in patient satisfaction [3].
Compression bandage therapy is an established treat-
ment of venous ulcers and lymphoedema, but efficacy in
TKA remains unclear due to conflicting results in the
literature and heterogeneous methodology. A feasibility
study has been performed [4, 5] and data from that
study suggested that the use of an inelastic, short-stretch
compression bandage following TKA is a safe technique
and that it was feasible to enlist surgical teams to recruit
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suitable patients. A large randomised controlled trial
(RCT) is needed to establish effectiveness.
Methods/design
This is a pragmatic, multicentre RCT investigating the
use of a two-layer compression bandage system com-
pared with a standard care (wool and crepe) bandage
following TKA.
The study includes an economic evaluation.
Objective
The objective is to determine the effectiveness and
cost-effectiveness of a two-layer compression bandage
compared with a standard wool and crepe bandage ap-
plied post-operatively on patient-reported outcomes in
TKA patients.
Setting
The Chief Investigator (CI) obtained initial agreements
to participate from orthopaedic units in National Health
Service (NHS) Hospital Trusts in the United Kingdom
across a range of urban and rural areas with the
provision of adding further interested centres. The prag-
matic design of the trial and wide clinician involvement
ensures immediate applicability and generalisability of
the trial findings. Two thousand and six hundred pa-
tients will be recruited from approximately 26 secondary
care orthopaedic units from across the UK. Table 1
shows a list of all participating hospital trusts sites that
have been set up to recruit patients into the trial.
Study participants
Patients are eligible to participate in this study if they: 1)
are scheduled for primary total knee arthroplasty; 2)
present at a participating trial site; 3) are aged 18 years
and over; and 4) are willing and able to provide written
informed consent.
Patients will be excluded from this study if they: 1) are
unable to provide informed consent; 2) have a history of
peripheral vascular disease; 3) have a history of periph-
eral neuropathy; 4) have a history of, or current, venous
ulceration; 5) have absent foot pulses; 6) are planned
same-day discharge joint replacement patients; 7) are
scheduled for revision knee arthroplasty; 8) are sched-
uled for Unicondylar or patellofemoral joint knee arthro-
plasty; 9) are prescribed regular concomitant high-dose
anti-coagulant medication (patients on routine thrombo-
prophylaxis can be included); 10) are unwilling to pro-
vide informed consent; 11) lack mental capacity and are
therefore unlikely to comply with data collection; 12) are
scheduled for bilateral knee replacement; or 13) have
been previously recruited into KReBS (now scheduled
for knee replacement on the opposite leg).
Additional clarification to accompany exclusion 9 was
issued to participating sites as follows:
This exclusion applies to high-risk patients, most likely
with metal heart valves who require anticoagulation
through the peri-operative period. These patients will
usually be given intravenous heparin instead of their
regular medications and should be clarified with the
operating surgeon if unsure. In usual practice these will
be rare.
The vast majority of patients on anti-coagulation will
be those taking warfarin, apixaban, rivaroxaban, etc. for
deep vein thrombosis (DVT), atrial fibrillation (AF), or
stroke prevention. They will have stopped this prior to
the operation and will restart it following the operation.
These patients should be included in the study.
Trial interventions
Standard care (control) group
The bandage will be applied over the routine surgical
wound dressing.
Table 1 KReBS participating hospital trust sites
Study sites
1. Northumbria Healthcare NHS Trust
2. Gateshead Health NHS Foundation Trust
3. York Teaching Hospital NHS Foundation Trust
4. North Cumbria University Hospitals NHS Foundation Trust
5. The Dudley Group NHS Foundation Trust
6. County Durham and Darlington NHS Foundation Trust
7. Royal Devon and Exeter NHS Foundation Trust
8. Hampshire Hospitals NHS Foundation Trust
9. North Tees and Hartlepool NHS Foundation Trust
10. East and North Hertfordshire NHS Trust
11. East Kent Hospitals University NHS Foundation Trust
12. South Tees Hospitals NHS Foundation Trust
13. Maidstone and Tunbridge Wells NHS Trust
14. Norfolk and Norwich University Hospitals NHS Foundation Trust
15. Taunton and Somerset NHS Foundation Trust
16. Manchester University NHS Foundation Trust
17 Warrington and Halton Hospitals NHS Foundation Trust
18. Wrightington, Wigan and Leigh NHS Foundation Trust
19. Western Sussex Hospitals NHS Foundation Trust
20. City Hospitals Sunderland NHS Foundation Trust
21. Dorset County Hospital NHS Foundation Trust
22. Betsi Cadwalder University Health Board
23. Golden Jubilee National Hospital
24. Stockport NHS Foundation Trust
25. University Hospitals Coventry and Warwickshire NHS Trust
26. Epsom and St. Helier University Hospitals NHS Trust
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The control treatment is one layer of soft synthetic
bandage applied from the proximal tibia to distal femur
covered by a further layer of crepe bandage prior to or
after tourniquet deflation, with 50% overlap of each
layer. Cryotherapy can be applied over this if part of rou-
tine care. The bandage should be removed between 24
and 48 h post-operatively with the dressing remaining in
situ.
Intervention group
The bandage will be applied over the routine surgical
wound dressing. Intervention bandage is applied from
the toes upwards. The application of the bandage from
thigh to groin requires removal of the tourniquet first,
keeping the leg elevated until the bandaging is complete.
Initially a foam inner bandage (Coban 2, 3M UK) is
applied from the toe to the groin on the affected leg with
minimal overlap. The second layer of compression ban-
dage (Coban 2, 3M UK) is applied at 50% stretch and
with a 50% overlap of bandage to ensure adequate com-
pression in the application.
To ensure homogeneity in bandage application, the
operating surgeons will be shown a training video on
correct application. The compression bandage is re-
moved on the planned day of discharge, at least 24 h fol-
lowing application. For patients not already discharged,
the compression bandage will be removed at 48 (± 4)
hours post-operation.
The bandages can be removed before 24 h if the pa-
tient finds them very uncomfortable, or in the event of
clinical need or any adverse occurrence that would re-
quire their removal.
Rehabilitation
For both the intervention and standard care groups, pa-
tients will receive physiotherapy as per routine care.
Outcome measures
Table 2 outlines the time points at which the outcomes
are assessed. These outcomes are described below.
Primary outcome
The primary outcome and end-point for the trial is the
Oxford Knee Score (OKS) total score at 12 months from
randomisation. OKS is a patient-reported outcome
measure specifically designed and developed to assess
function and pain after TKA surgery.
Secondary outcomes
 OKS at 6 months post-surgery.
 EuroQol 5 Dimensions (EQ-5D)-3 L index score at 6
months post-surgery.
Table 2 Study assessment schedule
Study period
Enrolment Allocation Post-allocation
Timepoint Baseline (pre-
randomisation)
Randomisation Day of
surgery
Approximately 10 days
post-surgery
Week
4
Month
6
Month
12
Enrolment
Eligibility screen x
Informed consent x
Allocation x
Interventions
Compression Bandage x
Standard care Bandage x
Assessments
Body mass index xa
Demographic data xa
Comorbidities xa
Oxford Knee Score xa xa x
EQ-5D-3 L xa xa x
EQ-5D-5 L x x
Pain scores (via SMS) x x x
Basic health economics data (i.e.
healthcare resource use)
x
EQ-5D EuroQol 5 Dimensions
aFrom routine data where possible
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 EQ-5D-3 L index score at 12 months post-
randomisation.
 EQ-5D-5 L index score at 12 months post-
randomisation.
 Pain scores at 10 days, 4 weeks, and 12 months post-
surgery (collected via SMS message for those partici-
pants that opt into receiving SMS messages as part
of the study).
 Length of hospital stay.
 Proportion of each patient group that: has to return
to theatre within 30 days of surgery for any reason;
is readmitted to hospital within 30 days of surgery
for any reason; suffers a pulmonary embolism (PE)
requiring inpatient hospitalisation within 30 days of
surgery; suffers a DVT requiring inpatient
hospitalisation within 30 days of surgery.
Participant timeline
Figure 1 illustrates the process of enrolling participants
into the study, the interventions being compared, and
timing of assessments for the participants in the trial.
Sub-studies
Text message
An embedded RCT will be undertaken to evaluate the
effectiveness of a personalised text message prompt, in-
cluding the participant’s name, compared with a stand-
ard text message on postal response rates to the
12-month questionnaire. This is separate to the collec-
tion of pain scores via SMS (all patients that consent to
receiving text messages will be asked to return pain
scores).
Text messages have been found to be effective for im-
proving completion and return of questionnaires in trials
[6]. Little research exists on the use of personalised text
messaging for improving trial response rates.
Participants will be randomised in a 1:1 ratio to re-
ceive a standard text message, or to personalised text
messages which includes their name with their
12-month follow-up questionnaire. Generation of the al-
location sequence will be undertaken independently by a
researcher not involved with the delivery of the text
messages, and will use simple randomisation. Partici-
pants are able to opt out of receiving text messages
without affecting participation in the main trial. There-
fore, the sample size of the text sub-study will be con-
strained by the number of participants that consent to
receiving text messages.
Participants will be sent the text messages at the same
time as they are expected to receive their postal
follow-up questionnaire (i.e. 2 to 4 days after the ques-
tionnaire is sent). Text messages are likely to be sent
using secure UK-based text message gateway software
such as that provided by Intelli Software (https://www.
intellisoftware.co.uk/).
The primary outcome of this embedded trial will be
the proportion of participants who return their question-
naire. Secondary outcomes will be time to response and
completeness of response.
Pen sub-study
We will undertake an embedded RCT to evaluate the ef-
fectiveness of including a pen with the 12-month ques-
tionnaire on response rates. Participants allocated to the
intervention group will receive a pen with the University
of York logo on it, whilst control participants will re-
ceive no pen. Participants will be randomised using sim-
ple randomisation in a 1:1 ratio.
All participants in the KReBS main trial will be eligible
to be included in the pen sub-study. There are no exclu-
sion criteria.
The primary outcome will be the proportion of partici-
pants who return the 12-month questionnaire. Second-
ary outcomes will be time to response and completeness
of response.
EQ-5D-3 L and -5 L order
We will undertake an embedded RCT to evaluate
whether the order in which the EQ-5D-3 L and -5 L ap-
pear in the 12-month questionnaire impacts on the par-
ticipant responses. Participants will be allocated using
simple randomisation in a 1:1 ratio to either receive a
questionnaire in which the EQ-5D-3 L appears before
the -5 L, or a version in which the EQ-5D-5 L appears
first. All participants due to be sent their 12-month
questionnaire will be included in this embedded trial.
Northumbria blood loss sub-study
Blood loss during and following TKA reduces a patient’s
haemoglobin and haematocrit counts whilst increasing
the need for blood transfusion. It has been hypothesised
that the use of a compression bandage will act as a tam-
ponade and help reduce this loss [7]. Acute
post-operative pain is also a concern and, from previous
studies, compression bandaging may help decrease a pa-
tient’s post-operative pain [8].
A subset of main trial participants undergoing TKA in
Northumbria NHS Foundation Trust will have their rou-
tinely taken pre- and post-operative full blood counts
and transfusion data reviewed as well as the first 24 h
post-operative pain scores and breakthrough analgesia
requirements.
The primary outcome measure of the embedded blood
loss sub-study will be the difference in haemoglobin
level changes between the two arms. Secondary outcome
measures will be the difference in haematocrit level
changes and inpatient transfusion rates. Secondary
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endpoints, additional to those specified in the main trial
protocol, will be length of stay, 24-h pain scores, and
breakthrough analgesia requirement as well as readmis-
sion and complications rates.
Our initial sample size calculations were for 207 pa-
tients to observe a difference of 1 g of haemoglobin (90%
power, SD 2.1). However, we adjusted this calculation to
take into account the pre- and post-test correlation and
a potential clustering around the surgeon.
A sample size of 156 (78 in each group) will give us
90% power to detect a difference in post-operative
haemoglobin level (the primary outcome measure)
between the intervention and control groups of 0.35 g/dl
(SD 0.7, which equates to an effect size of 0.5), assuming
a pre-post correlation of 0.7, 10% loss to follow-up, an
average of 60 procedures per consultant, and an ICC of
0.01.
This sub-study is being undertaken as part of a stu-
dent project and the results are to be reported separately
to those of the main trial.
Sample size
A standard deviation for the OKS of 8, an attrition rate
of 15%, and a clinically important difference of 3 points
Fig. 1 KReBS study flow chart. Figure illustrating the process of enrolling participants into the study, the interventions being compared, and
timing of assessments for the participants in the trial. BMI body mass index, EQ-5D EuroQol 5 Dimensions, OKS Oxford Knee Score, PROM Patient-
Reported Outcome Measure
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were determined from a preliminary feasibility study.
However, because the intervention is very inexpensive
and low-risk it could be argued that a smaller difference
than 3 may still be meaningful. Assuming a more con-
servative attrition rate (20%) than was observed in the
feasibility trial and powering at 80% to detect a 1-point
difference we need to recruit and randomise 2515 partic-
ipants. We have decided to round this to 2600. Further-
more, the power of the study does not include the
influence of covariates (e.g. baseline test score), which
will correlate with the outcome scores and provide in-
creased power from the adjusted regression analyses.
Recruitment
All patients scheduled for TKA who are deemed eligible
by their surgical team will be mailed information or
given information on the trial at a pre-operative visit.
Patients will be given sufficient time to accept or decline
involvement. Patients will be given the opportunity to
discuss the trial with research staff or their treating sur-
gical team prior to their surgery. Following confirmation
of eligibility, written informed consent will be obtained
by research staff prior to surgery. Participants will be
free to withdraw from the study at any time without af-
fecting their routine care.
Strategies for achieving adequate participant enrol-
ment to reach the target sample size include seeking ad-
vice from our patient representatives, sharing best
practice with our Research Nurses, and regular discus-
sion with our Principal Investigators (PIs).
Site staff will be provided with training at the site initi-
ation visits to ensure adherence to the delivery of the in-
terventions in the trial. During the trial, training and
reminders will be implemented using e-mail bulletins,
and discussion with the PIs and with Research Nurses.
In addition, the Trial Co-ordinators will provide support
and guidance to staff when required (e.g. when new staff
join or replace existing site staff ) and will seek clinical
guidance from the Chief Investigator (CI) when
necessary.
Randomisation
Simple, equal randomisation without stratification or
blocking will be used to generate the treatment alloca-
tion schedule. As the sample size of the trial exceeds 200
there is no loss of statistical efficiency compared with
using more complex (restricted) randomisation methods
[9].
When patients have given consent and their baseline
forms have been completed, the Research Nurse or
recruiting clinician will randomise them using the York
Trials Unit’s (YTU) secure, web-based randomisation
service. Patients will be allocated 1:1 to receive either
compression bandaging or standard care (wool and
crepe) bandaging, therefore ensuring allocation conceal-
ment and immediate unbiased allocation. Patients will
be informed of their allocations as will the clinician
managing each patient.
Data management
Paper case report forms (CRFs) will be used to record all
the information required from the protocol with the fol-
lowing exceptions: demographic, comorbidity, and com-
plications data will be downloaded from Patient
Administration Systems (PAS) at each site; pain scores
will be collected from participants via SMS message
where they have agreed to be contacted via this means;
and Patient-Reported Outcome Measures (PROMs) at
baseline and 6months post-surgery (OKS and EQ-5D-3
L) will be obtained via the NHS Digital’s PROMS project
(https://www.england.nhs.uk/statistics/statistical-work-
areas/proms/) and reported via participating sites to
YTU.
All data will be completely anonymised for the pur-
poses of analysis and any subsequent reports or publica-
tions. For the purposes of ongoing data management,
once randomised, individual participants will only be
identified by trial identification numbers to maintain
confidentiality.
All paper records will be kept in locked locations. All
consent forms will be secured safely in a separate com-
partment of a locked cabinet. Essential trial documenta-
tion (i.e. the documents which individually and
collectively permit evaluation of the conduct of a clinical
trial and the quality of the data produced) will be kept
with the Trial Master File and Investigator Site Files. At
the end of the study, paper copies of data will be se-
curely archived by participating sites and the University
of York for a minimum of 5 years. Electronic data will
be stored indefinitely.
Once YTU has completed the analysis and published
all intended scientific journals, data will be made avail-
able for other researchers for secondary analysis upon
request. Requests for access to data will be reviewed by
the CI and study sponsor.
Statistical analysis
A detailed analysis plan will be agreed with the com-
bined Trial Steering Committee (TSC) and Data Moni-
toring and Ethics Committee (DMEC) at an early stage
of the study, before all of the data have been collected.
Any subsequent amendments will be clearly stated and
justified. Analyses will be conducted following the prin-
ciples of intention-to-treat (ITT) with outcomes ana-
lysed according to the patients’ original, randomised
group irrespective of deviations based on
non-compliance, and significance tests will be two-sided
at the 5% level, unless otherwise stated.
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The primary analysis will compare total OKS scores
between the treatment groups at 12 months using a co-
variance pattern mixed model incorporating outcome
data at 6 and 12 months, adjusting as fixed effects for
age, gender, baseline score, time point, treatment group,
and a treatment group-by-time point interaction, and
hospital site as a random effect. Treatment effects in the
form of an adjusted mean difference will be presented
with an associated 95% confidence interval (CI) and p
value for both time points (6 and 12months). The pri-
mary end-point will be the treatment effect estimate at
12 months, while the treatment effect at 6 months will
serve as a secondary outcome. Pain score (at 10 days, 4
weeks, and 12 months) will be analysed similarly.
The proportion of participants who, within 30 days of
surgery, 1) return to theatre, 2) are readmitted to hos-
pital, 3) experience a PE requiring hospitalisation, and 4)
experience a DVT requiring hospitalisation will be com-
pared between the two groups using mixed effects logis-
tic regression models, adjusting for age and gender as
fixed effects, and hospital site as a random effect. The
treatment effect in the form of an odds ratio will be pre-
sented with an associated 95% CI and p value.
Length of hospital stay in days will be analysed via a
mixed effect Poisson, or negative binomial, regression
model as appropriate, adjusting for age and gender as
fixed effects, and hospital site as a random effect. An in-
cidence rate ratio, 95% CI and p value will be provided.
Interim analysis
There are no planned interim analyses for the trial or
stopping guidelines.
Cost-effectiveness analysis
An economic analysis will be undertaken to determine
the cost-effectiveness of compression bandages versus
standard bandages following TKA. This will take the
form of a cost-utility analysis, thereby incorporating the
impact on patients’ health-related quality of life. The
analysis will be conducted from the perspective of the
UK NHS and Personal Social Services (PSS), in line with
NICE recommendations.
Health benefits for the economic evaluation will be
measured in terms of quality-adjusted life years
(QALYs). The EuroQol EQ-5D-3 L will be used to obtain
utility values for use in the cost-utility analysis. QALYs
will be generated for each patient based on the area
under the curve approach (Richardson G). EQ-5D data
will be collected at baseline (pre-operatively) and 6
months post-operatively (both collected routinely via the
National PROMS programme) and at 12 months (via a
12-month follow-up participant questionnaire). At base-
line and 12 months, in addition to the EQ-5D-3 L, we
will also collect EQ-5D-5 L data to enable a mapping
exercise and to utilise the updated -5 L version of the
EQ-5D. An analysis of the order in which the EQ-5D-3
L and EQ-5D-5 L appear in the 12-month follow-up
questionnaire will be undertaken to assess ordering ef-
fects associated with the presentation of the two EQ-5D
versions.
Costs will be assessed for the two groups; healthcare
resource use data will be collected. Specifically, primary
care resource use (i.e. General Practitioner (GP), nurse,
physiotherapist, occupational therapist visits) and re-
source use in the hospital setting (i.e. hospital outpatient
appointments, inpatient stays, day cases, and accident
and emergency admissions) will be obtained using pa-
tient self-reported data from the 12-month follow-up
questionnaire. Data obtained via routine data collection
methods (e.g. outpatient visits) may also feed into the
economic analysis if available. Unit costs will then be ap-
plied to the quantities of resources utilised, for example
using NHS Reference Costs (Department of Health) and
Unit Costs of Health and Social Care [10]. In addition,
product/intervention costs such as bandages/equipment
will be costed and information relating to complications
will be incorporated for the two groups. Information on
patients’ return to work/activities will also be collected.
The within-trial analysis will use regression methods
to generate estimates of mean costs and health outcomes
(i.e. QALYs), allowing for correlation between cost and
outcome data, and will adjust for covariates. The results
will be presented in terms of incremental
cost-effectiveness ratios (ICERs), specifically the incre-
mental cost per QALY. Future costs and outcomes will
not be discounted due to the trial follow-up not exceed-
ing 12months. Multiple imputation methods will be
used to handle missing data where needed [11].
Cost-effectiveness acceptability curves will be produced
to explore the probability that compression bandages
will be cost-effective at different cost-effectiveness
thresholds [12]. Uncertainty will also be explored via
sensitivity analysis to investigate the impact of under-
lying assumptions of the analysis and key cost drivers in
terms of the cost-effectiveness results.
Adverse event management
Adverse events related to the participant’s trial-related
compression bandaging up to 1 month after their knee
operation will be collected. Adverse events considered to
be a consequence of the surgery will not be collected or
reported in the context of this study. Symptoms relating
to possible complications of surgery, inter-current ill-
ness, or any inpatient episode within 30 days of surgery
will be collected. Other than for fatalities, this procedure
does not apply to any other adverse events which may
occur during the trial which are unrelated to the trial
procedures.
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The severity and likely relationship of any adverse
events will be documented by the designated site clin-
ician. An event is defined as ‘related’ if the event was
due to the administration of any research procedure,
whereas an ‘unexpected event’ is defined as a type of
event not listed in the protocol as an expected occur-
rence. The relatedness of an event will be reviewed by
the Chief Investigator and the Trial Steering Committee.
Serious adverse events that are confirmed to be related
to the research and are unexpected will be reported to
the Research Ethics Committee (REC). All adverse
events will be routinely reported to the Trial Manage-
ment Group (TMG) and sponsor. The combined TSC/
DMEC will be responsible for reviewing related and un-
expected serious adverse events.
Quality control
Northumbria Healthcare NHS Foundation Trust has
agreed to be the lead sponsor for this project and take
overall responsibility for the quality of study conduct.
This study will be fully compliant with the Research
Governance Framework and MRC Good Clinical Prac-
tice Guidance.
A rigorous programme of quality control will be
undertaken. The day-to-day management of the trial will
be the responsibility of the Trial Co-ordinator based at
York Trials Unit. Regular meetings with the Trial Man-
agement Group will be held and will monitor adherence
to the trial protocols at the trial sites.
Due to the low-risk nature of this study, approval will
be sought from the funders to set up one Independent
Steering and Monitoring Committee to undertake the
roles traditionally undertaken separately by the TSC and
the DMEC. This committee will comprise of an Inde-
pendent Chair who will be a surgeon with expertise in
knee replacement surgery, a statistician, a member of
the Patient Group, the Chief Investigator, and Trial Co-
ordinator/Manager. Other study collaborators may also
attend the meeting. The independent members of the
committee will be allowed to see unblinded data. The
role of this committee will include the review of all ser-
ious adverse events which are thought to be
treatment-related and unexpected. The committee will
meet at least annually or more frequently if the commit-
tee requests.
Discussion
Protocol modifications
Important protocol modifications are those that are
likely to affect, to a significant degree: the safety, phys-
ical or mental integrity of the subjects of the study; the
scientific value of the study; or the conduct or manage-
ment of the study. These substantial amendments will
be submitted to the Health Research Authority (HRA)
and REC for approval, having first been agreed with the
Sponsor and TMG. Minor modifications to the protocol
will be agreed with the TMG before submission for ap-
proval to the HRA. All amendments will be imple-
mented in the NHS organisations in compliance with
HRA guidance. Trial participants will be written to, if
necessary, to explain any changes. All amendments,
whether substantial or not, will be listed in the published
Final Report.
Dissemination
This protocol is being made publicly available. The re-
sults will be disseminated in international, open-access
peer-reviewed journals, through the local networks and
at national and international meetings in surgical care. A
dissemination and publication policy will be developed
with an agreement between partners including owner-
ship and exploitation of intellectual property, and publi-
cation rights.
Following publication of the main trial findings, data
will be made available for other researchers for second-
ary analysis upon request. Requests for access to data
will be reviewed by the CI and study sponsor.
Trial status
The current REC approved version of the protocol is
version 3.0 (19 March 2018). This manuscript is a
restructured and edited version of the current REC ap-
proved protocol to comply with the SPIRIT guideline. A
completed SPRIT checklist can be found in Additional
file 1. Recruitment into the KReBS trial commenced in
March 2017 and is ongoing at the time of manuscript
submission. To date, 2150 patients have been rando-
mised (July 2018). Recruitment was originally scheduled
to end in February 2018. Early indications were that re-
cruitment targets would not be met due to early delays
with the R&D approval process at several of the origin-
ally planned sites and lag time taken to recruit the first
patient at several participating sites. An extension to re-
cruitment was discussed and recommended by the TMG
and TSC/DMEC and was agreed upon by the funders.
The recruitment phase has been extended to the end of
August 2018.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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